Features

Medical journal ad spend in H1 2017: All the data in one place

Medical journal ad spend in H1 2017: All the data in one place

By

The top three most advertised brands were GlaxoSmithKline's Breo Ellipta, Eli Lilly's Trulicity, and Boehringer Ingelheim's Jardiance.

The professional paths of 8 pharma execs

The professional paths of 8 pharma execs

By

The successes of these pharma execs show that there's no one path to professional bliss.

Healthcare agencies re-evaluate tactics to retain talent

Healthcare agencies re-evaluate tactics to retain talent

By

The best marketers possess a mix of scientific know-how, digital dexterity, and unflappability. To keep them, agencies need to revise their thinking and tactics.

Can marketing techniques save clinical trials?

Can marketing techniques save clinical trials?

By

No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.

Experts say pharma's move to Snapchat is in the making

Experts say pharma's move to Snapchat is in the making

By

Alone among the best-known social platforms, Snapchat has failed to generate much enthusiasm from pharma. Here's why — and here's why that may change.

Investors put their money on point of care

Investors put their money on point of care

By

Two recent cash infusions suggest investors are bullish on point-of-care advertising. Is the channel ready for its moment in the spotlight?

Drugmakers test out Tumblr, to tap specific audiences

Drugmakers test out Tumblr, to tap specific audiences

By By

Pharma has more or less ignored the social-blog hybrid Tumblr, with the number of programs using it countable on a single hand. That's about to change.

Healthcare agencies intensify college recruiting tactics

Healthcare agencies intensify college recruiting tactics

By

They are using social media campaigns, apprentice programs, and hands-on internships to recruit young, innovative talent right out of school.

Pharma companies, now marketing high-science drugs, rely more on medical affairs

Pharma companies, now marketing high-science drugs, rely more on medical affairs

By

Five years ago, the notion of medical science liaisons as a guiding voice in the marketing mix was borderline preposterous. Now they're called upon early and often.

Drugmakers turn to tech to better demonstrate empathy

Drugmakers turn to tech to better demonstrate empathy

By

Frustrated by its inability to empathize with patients, pharma has turned to tech to teach providers and caregivers what illness really feels like.

Top 40 Healthcare Transformers of 2017

Top 40 Healthcare Transformers of 2017

MM&M honors 40 upstarts and veteran innovation gurus.

Top 10 Innovation Catalysts of 2017

Top 10 Innovation Catalysts of 2017

For the first time MM&M honors a group of 10 agency execs.

Pro Ad Report: All the data on medical journal spending in 2016

Pro Ad Report: All the data on medical journal spending in 2016

By

The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.

Some CME experts remain skeptical when it comes to social media

Some CME experts remain skeptical when it comes to social media

By

There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.

Infographic: What's next for the point of care market

Infographic: What's next for the point of care market

About 30% of patients are more likely to fill a prescription after being exposed to healthcare ads at the point of care, according to Kantar Media.

What uncertainty? 72% of health marketers say 2017 budgets are up

What uncertainty? 72% of health marketers say 2017 budgets are up

By

This according to the 172 healthcare marketing executives who participated in the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.

Guidemark Health's Sophy Regelous on why small budgets are increasing

Guidemark Health's Sophy Regelous on why small budgets are increasing

By

Guidemark Health COO Sophy Regelous shares her perspective on the 2017 MM&M/Guidemark Health Healthcare Marketers Report.

Marketers take a new approach to lung-cancer campaigns, and why that matters

Marketers take a new approach to lung-cancer campaigns, and why that matters

By

Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.

Merck and Aetna pair population health with risk-sharing, in two deals

Merck and Aetna pair population health with risk-sharing, in two deals

By

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Ryan Abbate, 2017 MAHF inductee, sets the record straight

Ryan Abbate, 2017 MAHF inductee, sets the record straight

By

The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.

Mike Lazur, 2017 MAHF inductee, on his medical advertising destiny

Mike Lazur, 2017 MAHF inductee, on his medical advertising destiny

By

He played a leading role during Torre Lazur's glory era as "the launch agency." Now he is being inducted into the Medical Advertising Hall of Fame.

Trump administration raises questions for rare-disease drugmakers

Trump administration raises questions for rare-disease drugmakers

By

Nobody knows what the future holds for the Affordable Care Act under the Trump administration and an emboldened Republican Congress.

Shark Tank's Herjavec shares his tips for innovation competitions

Shark Tank's Herjavec shares his tips for innovation competitions

By

When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.

Japanese drugmakers lead the way in digital innovation

Japanese drugmakers lead the way in digital innovation

By

Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.

5 digital experts on what's next in health technology

5 digital experts on what's next in health technology

Read more to learn what Startup Health's Unity Stoakes and UCB's Greg Cohen, and others have to say about the latest trends for 2017.

Pharma adopts data-science culture in move toward AI

Pharma adopts data-science culture in move toward AI

By

Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.

Why healthbots may eat search ads and mobile apps

Why healthbots may eat search ads and mobile apps

By

The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.

Big data expert Hilary Mason on 3 ways to create a data-driven culture

Big data expert Hilary Mason on 3 ways to create a data-driven culture

By

The first step is to seek leadership support, she says.

The 2017 pipeline report: What to know about next year's launches

The 2017 pipeline report: What to know about next year's launches

By

Here's a look at 100 experimental therapies in late-stage clinical trials.

The doctor-patient dialogue: As productive as it's ever been or broken?

The doctor-patient dialogue: As productive as it's ever been or broken?

By

More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.

Infographic: The physician view on EHRs

Infographic: The physician view on EHRs

Most physicians said EHRs have negatively impacted their communication with a patients.

Evercore ISI's Umer Raffat on his predictions for pharma in 2017

Evercore ISI's Umer Raffat on his predictions for pharma in 2017

By

Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.

Will he or won't he? Pharma speculates on President-elect Trump

Will he or won't he? Pharma speculates on President-elect Trump

By

If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.

Drugmakers, facing pricing criticism, sell cures in new ads

Drugmakers, facing pricing criticism, sell cures in new ads

By

With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?

Insurers seek to challenge millennial 'invincibility'

Insurers seek to challenge millennial 'invincibility'

By

Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.

3 health tech innovations experts say will revolutionalize healthcare

3 health tech innovations experts say will revolutionalize healthcare

By

As digital-health funding increases, here's how VR, nanotechnology, and 3D printing could potentially improve the value of healthcare.

What do employers want? We ask three execs for their secrets and their insights

What do employers want? We ask three execs for their secrets and their insights

They share their insights, secrets, worries, and everything else in between.

The industry's winning — and losing — job titles, based on salary

The industry's winning — and losing — job titles, based on salary

Hint: it pays to be an EVP.

Pharma marketing salaries veer off track, dropping 2.6% in 2016

Pharma marketing salaries veer off track, dropping 2.6% in 2016

By

Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.

Sudler New York's John Marchese on the New Talent Pool

Sudler New York's John Marchese on the New Talent Pool

By

"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes marketers turn to big data, gaming to improve outcomes

By

Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.

The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

By

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

By

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.

Healthcare marketers: Don't forget about the baby boomers

Healthcare marketers: Don't forget about the baby boomers

By

Baby boomers have taken to health tech with surprising ease, opening up a wealth of opportunities for marketers savvy enough to pursue them.

The CIO, reimagined for pharma

The CIO, reimagined for pharma

By

Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.

Leadership Exchange: Engaging the Millennial Doctor

Leadership Exchange: Engaging the Millennial Doctor

By

In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.

Telehealth: Improving the customer experience but still an unknown for pharma

Telehealth: Improving the customer experience but still an unknown for pharma

By

Although telehealth is still in its early stages, it's building momentum — with good reason.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

By

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

What do physicians think about biosimilars?

What do physicians think about biosimilars?

By

A Sermo poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"

2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.